Latest filings (excl ownership)
10-K/A
2023 FY
Annual report (amended)
26 Apr 24
8-K
Regulation FD Disclosure
25 Apr 24
8-K
Regulation FD Disclosure
18 Apr 24
8-K
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
10 Apr 24
8-K
Other Events
8 Apr 24
8-K
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
27 Mar 24
8-K
Regulation FD Disclosure
25 Mar 24
8-K
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
25 Mar 24
8-K
Moleculin Reports Full Year 2023 Financial Results
22 Mar 24
10-K
2023 FY
Annual report
22 Mar 24
8-K
Guidance to be provided for clinical development strategy for advancement of Annamycin into potential AML pivotal registration study
20 Mar 24
8-K
Moleculin Announces Reverse Stock Split
19 Mar 24
8-K
Regulation FD Disclosure
29 Feb 24
8-K
Regulation FD Disclosure
22 Feb 24
424B3
Prospectus supplement
16 Feb 24
8-K
Regulation FD Disclosure
15 Feb 24
8-K
Regulation FD Disclosure
14 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
14 Feb 24
EFFECT
Notice of effectiveness
13 Feb 24
CORRESP
Correspondence with SEC
9 Feb 24
UPLOAD
Letter from SEC
9 Feb 24
S-1
IPO registration
2 Feb 24
8-K
Regulation FD Disclosure
24 Jan 24
DEF 14A
Definitive proxy
16 Jan 24
PRE 14A
Preliminary proxy
5 Jan 24
8-K
Departure of Directors or Certain Officers
5 Jan 24
424B5
Prospectus supplement for primary offering
22 Dec 23
8-K
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
21 Dec 23
8-K
Regulation FD Disclosure
18 Dec 23
8-K
Regulation FD Disclosure
11 Dec 23
8-K
Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL’s in Conjunction with ASH Annual Meeting
11 Dec 23
8-K
Regulation FD Disclosure
20 Nov 23
8-K
Regulation FD Disclosure
13 Nov 23
8-K
Regulation FD Disclosure
13 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Moleculin Reports Third Quarter 2023 Financial Results
13 Nov 23
8-K
Regulation FD Disclosure
7 Nov 23
8-K
Regulation FD Disclosure
6 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Nov 23
8-K
Regulation FD Disclosure
17 Oct 23
Latest ownership filings
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
4
Jonathan P. Foster
27 Dec 23
4
Robert E. George
27 Dec 23
4
WALTER V KLEMP
27 Dec 23
4
WALTER V KLEMP
13 Jul 23
4
WALTER V KLEMP
5 Jul 23
4
Jonathan P. Foster
26 Jun 23
4
WALTER V KLEMP
26 Jun 23
4
DONALD H PICKER
26 Jun 23
4
DONALD H PICKER
22 Jun 23
4
Jonathan P. Foster
22 Jun 23
4
WALTER V KLEMP
22 Jun 23
4
Jonathan P. Foster
20 Jun 23
4
WALTER V KLEMP
20 Jun 23
4
Joy Yan
26 May 23
4
Elizabeth Cermak
26 May 23
4
John M Climaco
26 May 23
4
MICHAEL D CANNON
26 May 23
4
Robert E. George
26 May 23
4
WALTER V KLEMP
28 Nov 22
4
WALTER V KLEMP
23 Nov 22
4
WALTER V KLEMP
18 Nov 22
4/A
WALTER V KLEMP
15 Jul 22
4/A
WALTER V KLEMP
15 Jul 22
4/A
WALTER V KLEMP
15 Jul 22
4
WALTER V KLEMP
13 Jul 22
4
WALTER V KLEMP
6 Jul 22
4
DONALD H PICKER
22 Jun 22
4
Jonathan P. Foster
22 Jun 22
4
WALTER V KLEMP
22 Jun 22
4
John M Climaco
22 Jun 22
4
Robert E. George
22 Jun 22
4
MICHAEL D CANNON
22 Jun 22
4
Elizabeth Cermak
22 Jun 22
4
Joy Yan
22 Jun 22
4
WALTER V KLEMP
21 Jun 22
4
Jonathan P. Foster
21 Jun 22
4
Joy Yan
2 Mar 22
3
Joy Yan
2 Mar 22
4
WALTER V KLEMP
12 Jul 21